Edodekin alfa Completed Phase 2 Trials for Melanoma / Intraocular Melanoma Treatment

Indications	Status	Purpose	Phase
DBCOND0020306 (Melanoma) DBCOND0028574 (Intraocular Melanoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00031733	Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma	Edodekin alfa (DB15631) GP-100 antigen (DB14800) Incomplete Freund's adjuvant (DB17475) Sargramostim (DB00020) Tyrosinase (DB16626)
NCT00003339	Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma	Edodekin alfa (DB15631) GP-100 antigen (DB14800) Incomplete Freund's adjuvant (DB17475) Tyrosinase (DB16626)